Some states are showing elevated levels of influenza according to officials from the Centers for Disease Control and Prevention (CDC). In a media briefing held on Dec. 3, 2012, Thomas R. Frieden, MD, MPH, director of the CDC, and Melinda Wharton, MD, acting director of CDCs National Center for Immunization and Respiratory Diseases, provided mid-season figures on U.S. influenza activity and vaccination rates.
Here are the details for influenza activity during week 47 (Nov. 18-24, 2012) in the U.S.:
- Viral Surveillance: Of 5,342 specimens tested and reported by U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories during week 47, 812 (15.2 percent) were positive for influenza.
- Novel Influenza A Virus: One human infection with a novel influenza A virus was reported.
- Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.
- Influenza-associated Pediatric Deaths: No influenza-associated pediatric deaths were reported.
- Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness (ILI) was 2.2 percent, which is at the national baseline of 2.2 percent. Five regions reported ILI above region-specific baseline levels. Five states experienced high ILI activity, two states experienced moderate ILI activity; four states experienced low ILI activity; New York City and 39 states experienced minimal ILI activity, and the District of Columbia had insufficient data.
- Geographic Spread of Influenza: The geographic spread of influenza in four states was reported as widespread; seven states reported regional activity; 19 states reported local activity; the District of Columbia and 18 states reported sporadic activity; Guam and one state reported no influenza activity, and Puerto Rico, the U.S. Virgin Islands and 1 state did not report.
During week 47, the following influenza activity was reported:
Widespread influenza activity was reported by four states (Alaska, Mississippi, New York, and South Carolina).
Regional influenza activity was reported by seven states (Alabama, Idaho, Iowa, Maine, Massachusetts, North Carolina, and Ohio).
Local influenza activity was reported by 19 states (Arkansas, Colorado, Connecticut, Georgia, Illinois, Kansas, Kentucky, Louisiana, Minnesota, Missouri, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin and Wyoming).
Sporadic influenza activity was reported by the District of Columbia, and 18 states (Arizona, California, Florida, Hawaii, Indiana, Maryland, Michigan, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Oklahoma, Pennsylvania, Washington, and West Virginia).
No influenza activity was reported by Guam and one state (Vermont).
Puerto Rico, the U.S. Virgin Islands, and one state (Delaware) did not report.
The CDC has antigenically characterized 140 influenza viruses [two 2009 H1N1 viruses, 90 influenza A (H3N2) viruses, and 48 influenza B viruses] collected by U.S. laboratories since Oct. 1, 2012. 2009 H1N1 [2]:
Both 2009 H1N1 viruses tested were characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2012-2013 influenza vaccine for the Northern Hemisphere.
Influenza A (H3N2) [90]:
All 90 H3N2 influenza viruses tested so far have been characterized as A/Victoria/361/2011-like, the influenza A (H3N2) component of the 2012-2013 Northern Hemisphere influenza vaccine.
Influenza B (B/Yamagata/16/88 and B/Victoria/02/87 lineages) [48]:
Yamagata Lineage [34]: Thirty-four (70.8 percent) of the 48 influenza B viruses tested so far this season have been characterized as B/Wisconsin/1/2010-like, the influenza B component of the 2012-2013 Northern Hemisphere influenza vaccine.
Victoria Lineage [14]: Fourteen (29.2 percent) of 48 influenza B viruses tested have been from the B/Victoria lineage of viruses
An annual flu vaccination is recommended for everyone six months of age and older as the first and most important step in protecting against flu viruses.
National Influenza Vaccination Week (NIVW) is being observed December 2-8, 2012. National Influenza Vaccination Week was established in 2005 to highlight the importance of continuing influenza vaccination in December and beyond.
For more statistics, visit: http://www.cdc.gov/flu/weekly/
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.